MENU
+Compare
NXTC
Stock ticker: NASDAQ
AS OF
Apr 23 closing price
Price
$0.42
Change
+$0.02 (+5.00%)
Capitalization
11.77M

NXTC NextCure Forecast, Technical & Fundamental Analysis

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function... Show more

Industry: #Biotechnology
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for NXTC with price predictions
Apr 23, 2025

NXTC in +13.85% Uptrend, advancing for three consecutive days on April 23, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NXTC advanced for three days, in of 216 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NXTC's RSI Indicator exited the oversold zone, of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 22, 2025. You may want to consider a long position or call options on NXTC as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NXTC just turned positive on April 17, 2025. Looking at past instances where NXTC's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NXTC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NXTC entered a downward trend on April 22, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.180) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.992).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NXTC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NXTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

NXTC is expected to report earnings to fall 9.52% to -37 cents per share on May 01

NextCure NXTC Stock Earnings Reports
Q1'25
Est.
$-0.38
Q4'24
Missed
by $0.08
Q3'24
Missed
by $0.06
Q2'24
Missed
by $0.17
Q1'24
Missed
by $0.17
The last earnings report on March 06 showed earnings per share of -41 cents, missing the estimate of -34 cents. With 210.84K shares outstanding, the current market capitalization sits at 11.77M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company which discovers and develops novel immuno medicines to treat cancer & immune related diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
9000 Virginia Manor Road
Phone
+1 240 399-4900
Employees
82
Web
https://www.nextcure.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRLB33.810.51
+1.53%
Proto Labs
SKT31.860.17
+0.54%
Tanger
GRNQ0.93N/A
N/A
Greenpro Capital Corp
BCBP8.69-0.16
-1.81%
BCB Bancorp
AVY170.25-4.58
-2.62%
Avery Dennison Corp

NXTC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NXTC has been loosely correlated with CYTK. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NXTC jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NXTC
1D Price
Change %
NXTC100%
+4.89%
CYTK - NXTC
37%
Loosely correlated
+0.50%
ORMP - NXTC
33%
Poorly correlated
+0.66%
ARMP - NXTC
33%
Poorly correlated
+1.08%
ALT - NXTC
33%
Poorly correlated
+2.47%
GOSS - NXTC
32%
Poorly correlated
+7.51%
More